COVID-19 and atrial fibrillation: Intercepting lines

Donniacuo, Maria; Angelis, Antonella De; Rafaniello, Concetta; Cianflone, Eleonora; Paolisso, Pasquale; Torella, Daniele; Sibilio, Gerolamo; Paolisso, Giuseppe; Castaldo, Giuseppe; Urbanek, Konrad; Rossi, Francesco; Berrino, Liberato; Cappetta, Donato

doi:10.3389/fcvm.2023.1093053

Cited by 23 publications

(18 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the possible mechanisms of this connection is implemented by changing the electrophysiological properties of atrial cells due to the development of myocardial inflammation ( 22 ). This is due to a cytokine storm and an increase in a vascular permeability ( 23 ). Another potential cause of AF is linked to an activation of sympathetic nervous system, which leads to an overload in cardiomyocytes ( 24 ).…”

Section: Resultsmentioning

confidence: 99%

Atrial fibrillation and COVID-19: an analysis of the ambulatory database

Sizova,

Zakharova,

Shindryaeva

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common heart rhythm disorder in clinical practice. It worsens the quality of life of patients, leads to an increase in the mortality rate because of its association with a high risk of thromboembolic complications. The current pandemic of a new coronavirus infection, which began in March 2020, was marked by an increase in cardiovascular diseases, including an increase in the number of patients with AF. That is why it is extremely relevant to find answers to questions about the association and mutual influence of AF and coronavirus infection to reduce the risk of vascular complications. However, most research in this area has focused on hospital patients. In this study, an electronic database of outpatients with AF, including patients with a history of COVID-19 infection was analyzed in order to assess the most significant risk factors for complications.

show abstract

Section: Resultsmentioning

confidence: 99%

Atrial fibrillation and COVID-19: an analysis of the ambulatory database

Sizova,

Zakharova,

Shindryaeva

et al. 2024

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…3 However, the intriguing link between COVID-19 and AF has created a particular focus in cardiovascular medicine, providing additional information about the underlying mechanisms, clinical implications, and potential therapeutic options. 4 Although there are variations in the prevalence of NOAF in COVID-19 as documented by prior studies, it is clear that it can affect how the disease manifests clinically. [5][6][7] The presence of NOAF in COVID-19 raises significant clinical and public health issues, related to the effect of NOAF in COVID-19 outcomes, such as mortality, hospitalization rates, and the course of…”

Section: Introductionmentioning

confidence: 93%

“…Several underlying cardiovascular and systemic conditions have been linked to atrial fibrillation 3 . However, the intriguing link between COVID‐19 and AF has created a particular focus in cardiovascular medicine, providing additional information about the underlying mechanisms, clinical implications, and potential therapeutic options 4 . Although there are variations in the prevalence of NOAF in COVID‐19 as documented by prior studies, it is clear that it can affect how the disease manifests clinically 5–7 …”

Section: Introductionmentioning

confidence: 99%

A systematic review and meta‐analysis of new‐onset atrial fibrillation in the context of COVID‐19 infection

Rathore,

Atulkar,

Remala

et al. 2024

Cardiovasc electrophysiol

View full text Add to dashboard Cite

New‐onset atrial fibrillation (NOAF) in COVID‐19 raises significant clinical and public health issues. This systematic review and meta‐analysis aims to compile and analyze the current literature on NOAF in COVID‐19 and give a more comprehensive understanding of the prevalence and outcomes of NOAF in COVID‐19. A comprehensive literature search was carried out using several databases. The random effect model using inverse variance method and DerSimonian and Laird estimator of Tua2 was used to calculate the pooled prevalence and associated 95% confidence interval (CI). Results for outcome analysis were presented as odds ratios (ORs) with 95% CI and pooled using the Mantel‐Haenszel random‐effects model. The pooled prevalence of NOAF in COVID‐19 was 7.8% (95% CI: 6.54%–9.32%),a pooled estimate from 30 articles (81 929 COVID‐19 patients). Furthermore, our analysis reported that COVID‐19 patients with NOAF had a higher risk of developing severe disease compared with COVID‐19 patients without a history of atrial fibrillation (OR = 4.78, 95% CI: 3.75–6.09) and COVID‐19 patients with a history of pre‐existing atrial fibrillation (OR = 2.75, 95% CI: 2.10–3.59). Similarly, our analysis also indicated that COVID‐19 patients with NOAF had a higher risk of all‐cause mortality compared with, COVID‐19 patients without a history of atrial fibrillation (OR = 3.83, 95% CI: 2.99–4.92) and COVID‐19 patients with a history of pre‐existing atrial fibrillation (OR = 2.32, 95% CI: 1.35–3.96). The meta‐analysis did not reveal any significant publication bias. The results indicate a strong correlation between NOAF and a higher risk of severe illness and mortality. These results emphasize the importance of careful surveillance, early detection, and customized NOAF management strategies to improve clinical outcomes for COVID‐19 patients.

show abstract

“…Частота ФП у пацієнтів з COVID-19 без серцево-судинних порушень та із ними становить приблизно 19-21 і 36 % відповідно [21,22].…”

Section: у рамках дослідження проведено аналіз щодо наявності в анамн...unclassified

The influence of a transferred infection of COVID-19 on the development of atrial fibrillation and changes in its course depending on clinical and anamnestic data

Sychov,

Stasyshena

2023

UJC

View full text Add to dashboard Cite

The aim – to study the influence of clinical and anamnestic characteristics, namely: arterial hypertension, coronary heart disease, diabetes, previous myocardial infarction, acute cerebrovascular accident, metabolic cardiomyopathy, of myocarditis in the anamnesis and chronic heart failure on the development of atrial fibrillation (AF) de novo or the deterioration of the course of an already existing arrhythmia in patients after suffering a coronavirus infection (CI).Materials and methods. The study involved 116 patients with AF who were hospitalized in the department of clinical arrhythmology and electrophysiology from September 20.09.2020 to 21.12.2021 and had a history of coronavirus infection (CI). The 1st group – 36 people (31 %) in whom AF occurred after CI. The 2nd group – 25 patients in whom the form of AF has changed. The 3rd group – 55 patients in whom the form of AF did not change. In the 3rd group, two subgroups were formed: 3A – 35 patients in whom, although the form of AF did not change, the frequency or duration of arrhythmia paroxysms increased, and 3B – 20 patients without significant changes in the course of AF. As the first control group (C1), 49 patients with AF without a history of CI were examined. The second control group (C2) was formed by 22 patients after a CI in whom AF did not develop.Results and discussion. In patients of the 1st group, hypertension occurred 1.4 times more often (p<0.001) than in the subjects of the 2С comparison group. The presence of hypertension, especially of the 3rd stage, increased the probability of the appearance of AF after a previous CI, which probably contributed to the emergence of a new, more serious form of AF and worsened the course of this arrhythmia. CHD was probably more common in patients of group 2, compared to group 3. Coronary heart disease was also statistically more frequent in patients of subgroup 3A – in patients in whom the form of AF did not change, but the course of the arrhythmia worsened – the frequency and duration of paroxysms increased, in contrast to the subgroup 3B, in whose patients the course of AF did not fundamentally change. In patients with AF who underwent CI and had a history of аcute violation of cerebral circulation, its course worsened, compared to group 3B, in which the course of this arrhythmia did not change (p<0.001). Myocarditis in the anamnesis was probably much more common in patients of the 1st group, in comparison with the C2 group. There was a significant difference between the frequency of myocarditis in the anamnesis in patients of the 2nd group, in which the form of AF after CI changed to a more severe one, and in the patients of the 3rd group, in which the form of this arrhythmia did not change. Diabetes significantly and reliably affected the deterioration of the course of AF in patients who had this arrhythmia before CI, and contributed to a change in the form of AF to a more unpleasant one (2nd group) in comparison with patients without a change in the form of this arrhythmia (3rd group). Metabolic cardiomyopathy was reliably significantly more common in patients of the 1st group compared to the C2 group. There is a big difference between the frequency of metabolic cardiomyopathy in patients of the 2nd group in comparison with the patients of the 3rd group. In the patients of the 2nd group, in whom the form of AF changed to a more threatening one. There were statistically more people with heart failure IIA, and a higher stage of HF in the digital form in equal to persons of the 3rd group, which included patients in whom the form of AF did not change.Conclusions. In patients with atrial fibrillation who suffered a coronavirus infection, the most common concomitant diseases were found to be: HF I–IIA stage – 92 % (in more than half of the cases – in 51.4 % it was HF IIA stage), arterial hypertension – 83 %, coronary heart disease – 60 %, myocarditis – 28 %, diabetes was recorded in 12 % of patients. Arterial hypertension, especially of the 3rd stage, myocarditis in the anamnesis, heart failure of the II A stage caused the appearance of paroxysms of AF de novo after the transferred coronavirus infection in the cohort of patients studied by us. The aforementioned factors, as well as ischemic heart disease, myocardial infarction, and acute cerebrovascular accident in the anamnesis, have been established as markers of the transformation of the paroxysmal form of atrial fibrillation into persistent, or persistent atrial fibrillation into a permanent form of this arrhythmia after being infected with COVID-19.

show abstract

COVID-19 and atrial fibrillation: Intercepting lines

Cited by 23 publications

References 112 publications

Atrial fibrillation and COVID-19: an analysis of the ambulatory database

Atrial fibrillation and COVID-19: an analysis of the ambulatory database

A systematic review and meta‐analysis of new‐onset atrial fibrillation in the context of COVID‐19 infection

The influence of a transferred infection of COVID-19 on the development of atrial fibrillation and changes in its course depending on clinical and anamnestic data

Contact Info

Product

Resources

About